Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 8:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 625 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lacrimal Apparatus Disease Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of TOP1630 for Dry Eye Syndrome

NCT03088605
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
TOP1630 Ophthalmic Solution, Placebo to TOP1630 Ophthalmic Solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Jun 25, 2026, 8:19 PM EDT
Terminated Not applicable Interventional

Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases

NCT03937856
View directory record Official record
Conditions
Inflammatory Arthritis, Scleroderma, Myositis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Vasculitis
Interventions
Calm- Mindfulness Meditation smartphone application
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Jun 25, 2026, 8:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability

NCT01013077
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Optive, Soothe, New Emulsion, Soothe, New Emulsion, Optive, New Emulsion, Optive, Soothe
Other
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jun 25, 2026, 8:19 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes

NCT03846453
View directory record Official record
Conditions
Dry Eye
Interventions
HL036 Ophthalmic Solution, Placebo
Biological
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
12
States / cities
Phoenix, Arizona • Newport Beach, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Jun 25, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction

NCT00755183
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
testosterone ophthalmic solution, vehicle of testosterone ophthalmic solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Jun 25, 2026, 8:19 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

NCT05136170
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Cenegermin, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Glendale, California • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jun 25, 2026, 8:19 PM EDT
Not listed Phase 3 Interventional

Study of EBI-005 in Dry Eye Disease (DED)

NCT02405039
View directory record Official record
Conditions
Dry Eye
Interventions
EBI-005, Placebo
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Birmingham, Alabama • Newport Beach, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Jun 25, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

NCT04391894
View directory record Official record
Conditions
Dry Eye
Interventions
ECF843, ECF843 vehicle
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
52
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jun 25, 2026, 8:19 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca

NCT00128245
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Pimecrolimus, Vehicle
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Jun 25, 2026, 8:19 PM EDT
Completed Phase 3 Interventional Results available

Immediate Office Probing vs Deferred Facility Probing for Nasolacrimal Duct Obstruction in Children 6 to <10 Months Old

NCT00780741
View directory record Official record
Conditions
Nasolacrimal Duct Obstruction
Interventions
Immediate Office Probing, Deferred Facility Probing
Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
6 Months to 10 Months
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Jun 25, 2026, 8:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Computer Screen Properties Study

NCT05042960
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Brightness
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Jun 25, 2026, 8:19 PM EDT
Completed Not applicable Interventional Results available

Multicenter Trial Evaluating Quality of Tears Produced by Nasal Neurostimulation

NCT02385292
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Oculeve Intranasal Lacrimal Neurostimulator
Device
Lead sponsor
Oculeve, Inc.
Industry
Eligibility
22 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Sacramento, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Jun 25, 2026, 8:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Clinical Evaluation of the InflammaDry Device for Detecting Dry Eye

NCT01692964
View directory record Official record
Conditions
Dysfunctional Tear Syndrome
Interventions
InflammaDry
Device
Lead sponsor
Rapid Pathogen Screening
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Bradenton, Florida • Springfield, Missouri • Johnson City, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Jun 25, 2026, 8:19 PM EDT
Completed Phase 2 Interventional

A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model

NCT00814944
View directory record Official record
Conditions
Dry Eye
Interventions
Sirolimus
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Jun 25, 2026, 8:19 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.

NCT02553772
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose Based Eye Drop, Carboxymethylcellulose Sodium 0.5%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
10
States / cities
Azusa, California • Burbank, California • Glendale, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Jun 25, 2026, 8:19 PM EDT
Completed No phase listed Observational Results available

Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal Sensation and Dry Eye

NCT01161771
View directory record Official record
Conditions
Dry Eye
Interventions
Cataract Surgery and Limbal relaxing incision
Procedure
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Long Island City, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Jun 25, 2026, 8:19 PM EDT
Completed Not applicable Interventional Results available

Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea

NCT03194698
View directory record Official record
Conditions
Ocular Rosacea, Dry Eye
Interventions
Intense Pulsed Light Treatment (IPL), Meibomian Gland Expression
Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Jun 25, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease

NCT04734210
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.02% Betamethasone Sodium Phosphate, 0.04% Betamethasone Sodium Phosphate, Placebo
Drug
Lead sponsor
Surface Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
28
States / cities
Dothan, Alabama • Azusa, California • Mission Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Jun 25, 2026, 8:19 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation

NCT02910713
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Intranasal Tear Neurostimulator
Device
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Louisville, Kentucky • Memphis, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Jun 25, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

Preventive Approach to Congenital Heart Block With Hydroxychloroquine

NCT01379573
View directory record Official record
Conditions
Congenital Heart Block, Neonatal Lupus, Autoantibody-Associated Heart Block
Interventions
Hydroxychloroquine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Jun 25, 2026, 8:19 PM EDT
Terminated Phase 2 Interventional Results available

Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects

NCT01316770
View directory record Official record
Conditions
Sjögren's Syndrome, Xerostomia
Interventions
Dexamethasone Parotid Irrigation, Placebo Parotid Irrigation
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Jun 25, 2026, 8:19 PM EDT
Completed Phase 2 Interventional

Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops

NCT00001731
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Sjogren's Syndrome
Interventions
Cyclosporin A
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 25, 2026, 8:19 PM EDT
Not listed Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

NCT06296966
View directory record Official record
Conditions
Dry Eye
Interventions
VSJ-110, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Jun 25, 2026, 8:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dextenza With ILUX for Treatment of MGD

NCT04658927
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Evaporative Dry Eye
Interventions
Dexamethasone, 0.4mg, Prednisone acetate, Control
Drug · Other
Lead sponsor
Warrenville Eyecare
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Jun 25, 2026, 8:19 PM EDT